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Abstract
Background: Current influenza vaccines, based on antibodies against surface antigens, are unable to provide
protection against newly emerging virus strains which differ from the vaccine strains. Therefore the population has to be
re-vaccinated annually. It is thus important to develop vaccines which induce protective immunity to a broad spectrum
of influenza viruses. This trial is designed to evaluate the immunogenicity and safety of FLU-v, a vaccine composed of
four synthetic peptides with conserved epitopes from influenza A and B strains expected to elicit both cell mediated
immunity (CMI) and humoral immunity providing protection against a broad spectrum of influenza viruses.
Methods: In a single-center, randomized, double-blind and placebo-controlled phase IIb trial, 222 healthy volunteers
aged 18–60 years will be randomized (2:2:1:1) to receive two injections of a suspension of 500 μg FLU-v in saline (arm 1),
one dose of emulsified 500 μg FLU-v in Montanide ISA-51 and water for injection (WFI) followed by one saline dose
(arm 2), two saline doses (arm 3), or one dose of Montanide ISA-51 and WFI emulsion followed by one saline
dose (arm 4). All injections will be given subcutaneously. Primary endpoints are safety and FLU-v induced CMI,
evaluated by cytokine production by antigen specific T cell populations (flow-cytometry and ELISA). Secondary
outcomes are measurements of antibody responses (ELISA and multiplex), whereas exploratory outcomes include
clinical efficacy and additional CMI assays (ELISpot) to show cross-reactivity.
Discussion: Broadly protective influenza vaccines able to provide protection against multiple strains of influenza are
urgently needed. FLU-v is a promising vaccine which has shown to trigger the cell-mediated immune response. The
dosages and formulations tested in this current trial are also estimated to induce antibody response. Therefore, both
cellular and humoral immune responses will be evaluated.
Trial registration: EudraCT number 2015–001932-38; retrospectively registered clinicaltrials.gov NCT02962908
(November 7th 2016).
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Background
Influenza virus is an important respiratory pathogen that
causes annual epidemics and more seldom global pan-
demics [1, 2]. Influenza disease is generally characterized
by an acute onset of fever, muscle and joint pain, and re-
spiratory symptoms (e.g. coughing, sneezing, running
nose, sore throat) [1, 3, 4]. The symptoms are in most
cases self-limiting. However, influenza is associated with
high mortality and morbidity rates, especially in the eld-
erly, children younger than two years of age, pregnant
women, and individuals suffering from chronic diseases
or weakened immune system [3, 4]. Typical complica-
tions from influenza infection which may result in hospi-
talizations and deaths include pneumonia, caused by the
primary influenza infection itself or secondary bacterial
infections, and the exacerbation of chronic illness (i.e.
pulmonary or cardiovascular diseases) [1, 4]. Depending
on the virulence of the strains circulating during a par-
ticular influenza season, three to five million cases of se-
vere illness and about 250.000 to 500.000 deaths can
occur worldwide [3, 5]. Influenza also has a significant
financial impact due to medical treatment, hospitaliza-
tions and work absenteeism [6].
The primary measure for preventing influenza disease
is vaccination [3, 4]. For over 70 years, public health
programs have included influenza vaccines that are able
to neutralize the virus by eliciting antibodies against the
surface antigens hemagglutinin (HA) and neuraminidase
(NA) [7]. HA is responsible for the entry of the virus
into the host cells through the attachment of the viral
antigen to the sialic-acid-containing receptors on the
host cell surface, whereas NA facilitates budding of
newly formed viral particles and viral movement along
the respiratory tract to the target cell by cleaving sialic
acid [8, 9]. HA and NA exhibit a high variability due to
continuous changes of the viral genome through anti-
genic drift or shift. Antigenic drift is caused by point
mutations occurring during viral replication which leads
to minor amino acid changes resulting in new circulat-
ing virus strains each year [1, 10]. Antigenic shift is an
abrupt and major change of influenza virus due to gen-
etic re-assortment between human and other animal in-
fluenza viruses when a host is co-infected by both
viruses [1, 10]. Occasionally, these antigenic shifts result
in new influenza A subtypes that have not been circulating
in the human population before causing pandemics [1, 2].
Current influenza vaccines are safe and effective. How-
ever, the efficacy and effectiveness is limited. Due to on-
going antigenic drift, the influenza vaccine has to be
updated annually and the population has to be re-
vaccinated. Efficacy of the vaccine is mainly dependent
on the degree of similarity between the vaccine and the
circulating strains [11]. When having a good match, vac-
cination can reduce the risk of illness by 50–60% among
the overall population [11]. However, a mismatch situ-
ation can reduce the vaccine protective efficacy drastic-
ally leading to more influenza related hospitalizations
and deaths. A mismatch occurs due the fact that manu-
facturing of the vaccine must start 6 months in advance
of the influenza season. The World Health Organization
can only predict based on epidemiological studies which
influenza strains are likely to circulate. However, the
prediction is not always accurate or new strains can
emerge that could not have been predicted. Thus, there
is a need for influenza vaccines that protect the popula-
tion against a broad spectrum of influenza viruses, in-
cluding both seasonal and pandemic strains.
FLU-v was developed by SEEK (UK) to provide broad
spectrum protection against influenza. Initially FLU-v
will be administrated in conjunction with the annual in-
fluenza vaccine to broaden the protection and protect
subjects in case of vaccine mismatch. FLU-v contains a
sterile equimolar mixture of four synthetic polypeptides
that cover highly conserved regions (regions that do not
undergo antigenic changes) from the nucleoprotein
(NP), matrix 1 (M1) and matrix 2 (M2) proteins of both
the human and animal influenza A and B virus strains.
NP, M1 and M2 are internal proteins which play an im-
portant role in the stimulation of T-cell responses during
influenza infection [12]. Based on previous clinical stud-
ies, FLU-v primarily triggers cell-mediated immune re-
sponses [13]; however the dosages and formulations to
be tested in this current trial are also estimated to in-
duce antibody responses. These cellular and humoral re-
sponses are expected to mediate cross-protection against
different influenza viruses. In this phase IIb trial the im-
munogenicity and safety of FLU-v will be evaluated in
healthy volunteers aged 18 to 60 years. Immune re-
sponses to two different treatment options, one dose of
adjuvanted FLU-v or two doses of non-adjuvanted FLU-
v, will be assessed. Immunogenicity will be evaluated by
measurement of influenza-specific cell-mediated im-
munity (CMI) and humoral responses. Cross-reactivity
will be studied by ELISpot. Safety will be evaluated based
on the reported adverse events (AEs) and serious ad-
verse events (SAEs) during the study period. In addition,
clinical efficacy will be evaluated as an exploratory end-
point by assessing the number of reverse transcriptase
polymerase chain reaction (RT-PCR) confirmed influ-
enza cases and the severity of disease symptoms.
Method/design
Study design
The immunogenicity and safety of FLU- v will be evalu-
ated in a single-center, randomized, double-blinded and
placebo-controlled trial. The study will be conducted at
the Isala Clinics (Zwolle, The Netherlands). A total of
222 healthy volunteers aged 18 to 60 years will be
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recruited and followed for up to 6 months from screen-
ing to study conclusion. Individuals volunteering for the
trial will be screened for their eligibility before enroll-
ment. Written consent will be obtained during the
screening visit (Figure 1). Eligible subjects will be
randomized to receive one of four treatments; (1) two
doses of FLU-v as a suspension in saline, (2) one dose of
FLU-v as an emulsion in Montanide ISA-51 and water
for injection (WFI) followed by one dose of saline, (3)
two doses of saline, or (4) one dose of WFI and Monta-
nide ISA-51 emulsion, followed by one dose of saline.
All administrations will be given subcutaneously (s.c.)
21 ± 3 days apart. Blood samples will be taken from all
subjects on day 0 (before the first administration), day
42 (21 days after the second administration) and day 180
(159 days after the second administration) for the evalu-
ation of short term and long term vaccine-specific cellu-
lar and humoral immune responses. AE questionnaires
will be issued on day 0 and 21 to subjects to follow soli-
cited AEs. The questionnaires will need to be completed
by the subjects and returned on day 21 and day 42. The
incidence and nature of unsolicited AEs and SAEs will
be followed during the whole study period. In addition,
during the influenza season 2016–2017 subjects will
need to record influenza symptoms daily by means of a
web-based questionnaire. Subjects will receive a daily re-
minder to complete the questionnaire. Subjects will be
instructed to record influenza symptoms and when sub-
ject experiences a sudden onset (within 24 h) of at least
one respiratory (cough, sore throat, shortness of breath,
runny nose, stuffy nose, sneezing and earache) and one
systemic symptom (fever, malaise, headache and myalgia
(muscle and joint pain)), nasal and tonsil samples will be
taken within three days from contacting the subject or
within four days of the onset of symptoms, whatever
time is shorter. Confirmation of influenza infection will
be performed by RT-PCR assay.
Participants
Healthy males and females between the ages of 18 and
60 years are eligible for the study (Table 1). Pregnant or
breast-feeding women, individuals who have received an
influenza vaccine or have experienced influenza-like-
illness within the 6 months prior to the study, those who
are receiving medication or treatment that may affect
the evaluation of their immune responses and those who
have a history of chronic disease and/or immune system
disorder will be excluded from trial participation
(Table 1). Women of childbearing potential and men
must agree to practice adequate contraception throughout
the study treatment (up to day 51 (for female) and day
111 (for males)). Furthermore, individuals should be able
to understand and comply with the planned study proce-
dures and provide a signed informed consent form after
Fig. 1 Flow chart of the study’s design
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receiving a detailed explanation of the study protocol prior
to any of the study procedures. In case of uncertainty
about the medical status of an individual regarding any of
the exclusion criteria, the primary care physician will be
consulted. Consultation of the primary care physician is
included in the consent form and will only be related to
medical information about the exclusion criteria.
Screening and baseline assessment
To ensure the health of subjects before entering the trial,
a general physical examination will be performed during
the screening visit and a blood sample will be collected for
laboratory tests including hematology (e.g. hemoglobin,
red blood cell count, platelet count) and serum chemistry
(e.g. uric acid, creatinine, albumin, glucose). Female sub-
jects will also be subjected to a blood pregnancy test. Sub-
jects with a clinically significant abnormal test result will
be excluded from the study. Additional information on
demographics, self-reported medical and medication
Table 1 Trial inclusion and exclusion criteria trial subjects
Inclusion criteria - Aged between 18 and 60 years
- Healthy males and healthy non-pregnant females
(as indicated by a negative blood pregnancy test
during the screening visit)
- Healthy as determined by vital signs (heart rate,
blood pressure, oral temperature), blood chemistry
test (electrolytes, renal/kidney function, liver
function, C-reactive protein, complete blood
count), medical history, general physical
examination, self-reported illness and the clinical
judgment of the investigator
- Women of childbearing potential (not surgically
sterile or postmenopausal for ≥1 year) and men
must agree to practice adequate contraception
(a combination of barrier and hormone methods
for women and a condom for men) throughout
the study treatment for at least up 30 days
(to day 51 for females) and 90 days (to 111 for
males) after the last vaccination
- Able to understand and comply with planned
study procedures
- Provides signed informed consent form after
receiving a detailed explanation of the study
protocol prior to any study procedures
Exclusion criteria - Known allergy to any of the components of
the vaccine
- History of severe reactions following
immunization
- Immune deficiency/disorder, whether due to
genetic defect, immunodeficiency disease,
or immunosuppressive therapy
- Positive pregnancy test during the screening
visit or who are breastfeeding
- History of (reported by subjects):
Acute disseminated encephalomyelitis (ADEM);
Neoplastic disease – current or previous;
Asthma or severe allergic disease;
Bleeding disorders;
Chronic hepatitis B and/or C infection;
Chronic liver disease;
Diabetes mellitus;
Guillain-Barre syndrome;
Human immunodeficiency virus (HIV);
Rheumatoid arthritis or other autoimmune diseases;
Severe renal disease;
Transplant recipients;
Unstable or progressive neurological disorders
- Receipt of medicines/treatment that may affect
the evaluation of immunogenicity such as;
Oral or parenteral steroids, high-dose inhaled
steroids (greater than 800 micrograms/day of
beclomethasone dipropionate or equivalent) or
other immunosuppressive or cytotoxic drugs
(within the 6 months prior to vaccination in
this study);
Immunoglobulin or other blood products
(within the 3 months prior to vaccination in
this study);
Experimental agent (vaccine, drug, biologic,
device, blood product, or medication) within
1 month prior to vaccination in this study,
or expects to receive an experimental agent
during the study period;
Table 1 Trial inclusion and exclusion criteria trial subjects
(Continued)
Influenza antiviral medication within the 4 weeks
prior to the vaccination in this study.
- Received any influenza vaccine within 6 months
prior to vaccination in this study.
- Influenza like-illness (a sudden onset of symptoms
and at least one of the four systemic symptoms
fever, or feverishness, malaise, headache, myalgia
and at least one of the three respiratory symptoms
cough, sore throat, shortness of breath) or acute
respiratory infection (a sudden onset of symptoms
and at least of the four respiratory symptoms
cough, sore throat, shortness of breath, coryza and
a clinician’s judgment that the illness is due to an
infection) within 6 months prior to vaccination in
this study. These symptoms must have stopped
the subject from carrying out their normal daily
activities such as attending work or school for a
period of at least 3 days.
- Acute illness, including an oral temperature
greater than 38 °C, within 1 week before
vaccination.
- History of alcohol or drug abuse within the last
2 years deemed unsuitable for inclusion by the
investigator.
- Any abnormal haematology values and/or
serum chemistries judged by the investigator
as clinically significant.
- Ineligible subject based on the judgement of
the investigator.
In case there is uncertainty about the participant’s
medical status regarding any of the exclusion
criteria mentioned, the participant’s primary care
physician will be consulted. Consultation of the
primary care physician will only take place after
having received written approval from the
participant, and will concern medical information
about exclusion criteria only.
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history, influenza vaccination history, and alcohol, drug
and cigarette consumption will also be recorded. Each
screened subject will receive a sequential screening num-
ber which the subjects will retain whether or not they are
ultimately randomized to receive study treatment. Base-
line serum samples (day 0) will be stored until the end of
the trial to measure the hemagglutination inhibition (HI)
antibody titers against the influenza virus strains circulat-
ing during the 2016–2017 season, since presence of such
antibodies could have provided the subject a certain de-
gree of protection against infection with those strains thus
affecting the vaccine efficacy data.
Interventions
Subjects eligible for the study will be randomized to one
of the four treatment arms (ratio 2:2:1:1) as described in
Table 2. Subjects in arm 1 will receive two doses of 500
microgram (μg) non-adjuvanted FLU-v in suspension in
0.5 ml of saline (made by adding 0.25 ml of 0.01 M HCl
followed by 0.25 ml of 0.01 M NaOH). Subjects in arm 2
will receive one dose of adjuvanted 500 μg FLU-v as an
emulsion made with 0.25 ml of Montanide ISA-51 and
0.25 ml of WFI, followed by one dose of 0.5 ml of saline.
Two reference products will be used as controls for arm
1 and 2. In arm 3 subjects will receive two 0.5 ml doses
of saline as a control for those receiving non-adjuvanted
FLU-v (arm 1). Subjects in arm 4 will receive one dose
of 0.5 ml emulsion prepared with 0.25 ml of WFI and
0.25 ml of Montanide ISA-51, followed by 0.5 ml of sa-
line as a control for those receiving the adjuvanted
emulsion of FLU-v (arm 2). All treatments will be given
as a subcutaneous injection in the upper section of the
arm with an interval of 21 ± 3 days between the two
doses.
Outcomes
Primary outcomes
The primary outcomes of the study are safety and Th1
CMI responses elicited by FLU-v. Safety evaluation will
include the solicited AEs in all subjects until 21 days
after the last administration of the study vaccine and the
unsolicited AEs and SAEs in all subjects during the
whole study period. The intensity and causality of all re-
ported AEs will be assessed by the investigator (Table 3).
CMI at days 0, 42 and 180 will be evaluated by intracel-
lular cytokine staining (ICS) analysis after 24 h of in
vitro stimulation of peripheral blood mononuclear cells
(PBMC) with vaccine antigen. This analysis will inform
about the cytokine pattern (interleukin (IL) 2, interferon
gamma (IFN-γ) and tumour necrosis factor alpha
(TNFα)), phenotypic markers (clusters of differentiation
3 (CD-3), CD-4 and CD-8) and cytotoxic potential
(CD107a) of antigen specific T cell populations activated
by the vaccine. Vaccine specific Th1 responses will also
be evaluated by IFN-γ enzyme-linked immunosorbent
assay (ELISA) in supernatants from PBMC cultures ex-
posed to the same antigens.
Table 2 Vaccination schedule
Arm Administration 1 (day 0) Administration 2 (day 21)
1 500 μg FLU-v in 0.5 ml salinea
(suspension)
500 μg FLU-v in 0.5 ml
salinea (suspension)
2 500 μg FLU-v in 0.25 ml WFI and
0.25 ml Montanide ISA-51 (emulsion)
0.5 ml saline (solution)
3 0.5 ml saline (solution) 0.5 ml saline (solution)
4 0.25 ml WFI and 0.25 ml Montanide
ISA-51(emulsion)
0.5 ml saline (solution)
aMade by mixing 0.25 ml of 0.01 M HCl and 0.25 ml 0.01 sM NaOH
Table 3 Adverse events classification
Adverse event intensity
Mild An event that is easily tolerated by the subject,
causing minimal discomfort and not interfering
with everyday activities
Moderate An event that causes sufficient discomfort as to
interfere with normal everyday activities
Severe An event that prevents normal everyday activities
Serious Any untoward medical occurrence that:
o Results in death
o Is life threating (an event in which the subject
was at risk of death at the time of the event)
o Requires hospitalization or prolongation of an
existing hospitalization
o Results in disability or permanent damage as
defined as a substantial disruption of a person’s
ability to conduct normal life functions
o Is a congenital anomaly/birth defect
o Other adverse events that may jeopardize the
subject or may require medical or surgical
intervention to prevent one of the other
outcomes
Adverse event causality
Unrelated Where an event is not considered related to the
investigational medicinal product
Unlikely Although the relationship to investigational
medicinal product cannot be completely ruled
out, the nature of the event, the underlying
disease, concomitant medication or temporal
relationship make other explanations more likely
Possibly related The temporal relationship and the absence of a
more likely explanation suggest the event could
be related to the investigational medicinal
product
Probably related The known effects of the investigational medicinal
product or its therapeutic class, or based on
challenge testing, suggest the investigational
medicinal product is the most likely cause
Definitely related This category applies to those AEs that are clearly
a consequence of administration of the drug. It is
likely that such events will be widely documented
and generally accepted as having association
with the study medication.
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Secondary outcomes
Secondary outcomes are the evaluation of antibody re-
sponses specific for FLU-v at days 0, 42 and 180 ana-
lyzed by total Ig ELISA, followed by isotyping the
antibody response using a multiplex approach in sam-
ples with high FLU-v specific Ig titer.
Exploratory outcome
Exploratory outcomes are (1) FLU-v cross-reactive im-
munity evaluated with additional CMI assays such as
dual ELISpot for IFN-γ and granzyme B, and (2) clinical
efficacy of the FLU-v vaccine. Clinical efficacy will be
evaluated as the reduction of the incidence of RT-PCR
confirmed influenza A and/or B infections and the re-
duction in the symptom scores in subjects with con-
firmed influenza infections during the 2016–2017
influenza season. The relationship between efficacy and
the immune response will be explored if possible. More-
over, the effect of previous influenza vaccination on the
immunogenicity of FLU-v will be assessed in a post-hoc
exploratory analysis with data stratified by the length of
time between the last influenza vaccination and the
current study treatment.
Sample size calculation
The sample size is determined on the basis of influenza
specific IFN-γ responses since this is one of the most
important CMI markers for protection against influenza
[14, 15]. Based on a previous phase I trial with FLU-v it
is expected that at least a two-fold increase in the IFN-γ
response measured with ELISA will be observed in the
FLU-v non-adjuvanted arm (arm 1) when compared to
the non-adjuvanted placebo (arm 3) [13]. In comparison,
a five-fold increase in the IFN-γ response is expected to
be observed in the adjuvanted-FLU-v arm (arm 2) when
compared to the adjuvanted-placebo (arm 4). Hypothe-
sizing, a 2.5-fold increase in the IFN- γ response in the
adjuvanted FLU-v arm compared with the non-adjuvanted
arm and based on a two-sided type I test with a 95% confi-
dence interval taking into account loss to follow-up of
28% and a 2:1 ratio allocation (antigen vs. placebo), a total
of 222 subjects are required to measure significant differ-
ences between the treatment arms. For both active arms
(arm 1 and 2) and both placebo arms (arm 3 and 4) 74
and 37 subjects are required, respectively.
Randomization
Each subject screened will be allocated a screening num-
ber representing the sequential order in which they are
screened. Eligible subjects will be randomized to the four
treatment arms. Within each treatment group block
randomization will be performed based on the age of the
participant (18 to 40 years and 41 to 60 years) to achieve
an approximate balanced age distribution [16]. Subjects
will be allocated to the next sequential randomization
number available at the trial site. Randomization numbers
will be generated by the web-based system ALEA [17].
Blinding
The study will be double-blinded. Preparation of the for-
mulations will be performed by a trained person other
than the person vaccinating the subjects. Because an
emulsion of Montanide ISA-51 and WFI results in a
white liquid formulation, the blinded personnel will only
be blinded to the presence of antigen (FLU-v) but not
the presence of adjuvant (Montanide ISA-51). The syrin-
ges will be labeled with the study number, name of the
sponsor, dose, randomization number, date and time of
vaccine preparation. The person responsible for the
preparation of the formulation will assign each subject
to the appropriate treatment group based on the study
randomization code. He or she will not reveal the treat-
ment code to the blinded study personnel or perform
other study related activities. The pharmacy file includ-
ing the randomization list, vaccine supplies and all asso-
ciated documentation will be stored in a locked cabinet
within the pharmacy where only non-blinded personnel
have granted access.
Data management
The trial coordinating center (TCC) of the University
Medical Center Groningen (The Netherlands) will per-
form the data management during the trial. TCC will de-
velop an interactive website which will be the major
communication instrument to ensure the integration of
the program communication and the trial study. Fur-
thermore, TCC will develop electronic case report forms
(eCRFs) which will be optimized for scalability in ac-
cordance with the Good Clinical Practice (GCP) stan-
dards for electronic data entry and flexible export. The
eCRFs will be integrated in the interactive website. Data
entered into the website will be stored in a database for
consistency checks and will be backed up on a daily
basis. The database is subjected to secure access control
management to allow secure entry, access, analysis and
export of data by users and it is also subjected to plausi-
bility and consistency check during the entry process.
To ensure personal data protection, all nominal data
from subjects will be anonymized.
Statistical analysis and report
A statistical analysis plan (SAP) will be developed ac-
cording to the Consolidated Standards of Reporting
Trials (CONSORT) 2010 guidelines before the end of
the trial [18]. In general, both intention-to-treat (ITT)
and per-protocol (PP) analysis will be conducted for the
analyses of the CMI and antibody responses, and the re-
ported AEs and SAEs. ITT analysis will include all
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subjects randomized to receive treatment, irrespective of
whether they receive any injections. Subjects who meet
the inclusion/exclusion criteria, who comply with the
procedures defined in the protocol (i.e. received both
vaccinations according to the randomization schedule,
provided blood samples for immunogenicity assays on
days 0, 42 and 180, not vaccinated with any vaccine or
treated with any medication forbidden in the protocol,
not with underlying medical conditions forbidden by the
protocol) and never have the randomization code broken
will be included in the per-protocol analyses. In addition,
for safety evaluation all subjects who received at least
one injection will be included.
The primary and secondary analysis for specific T-cell
responses will be conducted with the PP population
using mixed models repeated measures analysis
(MMRM), with the baseline level as a covariate. All esti-
mates of treatment differences will be accompanied by
95% confidence interval (CI). For safety, the incidence
rate of at least one AE, at least one systemic AE, all soli-
cited AE, any AE, and at least one SAE will be presented
with associated 95% CI for each treatment group. SAEs
and withdrawals due to AEs will be described in detail.
The evaluation of the clinical efficacy will be conducted
with the ITT population; for each treatment group the
incidence rate of subjects with RT-PCR-confirmed influ-
enza A and/or B will be presented with 95% CI. Scores
on a scale of 0 to 3 will be requested for the following
symptoms: fever (> 38 °C), malaise, headache, myalgia
(muscle and joint point), cough, sore throat, shortness of
breath, runny nose, stuffy nose, sneezing and earache.
The scores are defined as: 0 = no symptoms, 1 = just no-
ticeable (mild), 2 = bothersome but can still do daily ac-
tivities (moderate), and 3 = bothersome and cannot do
daily activities (severe). The severity of the influenza
symptoms among the laboratory-confirmed influenza
cases will be summarized in tables of descriptive statis-
tics. In addition, an exploratory analysis will look at the
relationship between clinical efficacy and the CMI and
humoral responses.
Discussion
This phase IIb trial is designed to evaluate the immuno-
genicity and safety of different doses and formulations of
FLU-v. A previous phase I trial showed that FLU-v adju-
vanted with Montanide ISA-51 elicited cellular immune
responses which are important for the protection against
influenza illness. In that study the cellular immune re-
sponse was measured by IFN-γ ELISA. More than a 2-
fold increase in IFN-γ was detected in 80 and 100% of
subjects who received adjuvanted FLU-v at a low
(250 μg) or high dose (500 μg) after 21 days post-
vaccination compared to pre-vaccination, respectively
[13]. Since the sample size in this study is determined by
the earlier trial data obtained with the IFN-γ ELISA
assay, this assay is also included as the primary CMI
measurement. However, to obtain better quantitative
and qualitative insights into the vaccine elicited CMI re-
sponses, ICS will also be used to in this phase IIb trial.
ICS is an efficient method for simultaneous measure-
ment of antigen specific T cell populations (CD4, CD8)
with regard to their putative effector functions (CD107a)
and cytokine production capacities (IFN-γ, IL-2, IL-4
and TNFα) [14, 15, 19, 20]. The ICS analysis have been
standardized and validated. Aside from the primary CMI
assays, additional T cell based assays such as dual
ELISpot (IFN-γ and granzyme B) will be performed
as an exploratory endpoint since ELISpot has shown
to be a sensitive assay to measure influenza-specific
CMI [21, 22].
The humoral immune response elicited by FLU-v will
be evaluated as a secondary endpoint (total Ig ELISA
against the vaccine antigens). Since the vaccine targets
internal protein antigens of influenza virus, the vaccine-
elicited antibodies are not expected to have neutralizing
capacity, but the antibodies could still play a role in
activating complement, phagocytosis, or antibody-
dependent cellular cytotoxicity (ADCC) that would fa-
cilitate killing of influenza-infected cells [23]. In this
context, analysis of the Ig subclasses in those serum
samples showing high FLU-v specific total Ig titers could
provide important information about the putative ef-
fector role of FLU-v specific antibodies. Following this,
functional assays like ADCC or complement activation
could therefore be considered to confirm the role of the
FLU-v specific antibodies to combat influenza infected
cells. Although FLU-v specific antibodies were low in
the previous trial, changes in the vaccine formulation
and immunisation schedule are expected to increase the
antibody titers in this study.
As an exploratory endpoint the clinical efficacy will be
evaluated. This will be determined by the reduction in
the incidence of influenza infections and the clinical
symptom severity in RT-PCR-confirmed cases during
the 2016–2017 influenza season. The symptom scores
are determined with a standardised scoring system based
on subject-self assessment. This scoring system has been
used in a previous phase Ib challenge study in which
subjects were challenged with an influenza A virus
21 days after receiving a single dose of 500 μg FLU-v
adjuvanted with Montanide ISA-51 or WFI with Monta-
nide ISA-51. In this study investigators found a signifi-
cant correlation between an increased IFN-γ response
and the total symptom score [24]. Although there is not
enough power to demonstrate statistical significant
clinical efficacy in the current study, there is a chance to
investigate immune correlates of protection if the influ-
enza season of 2016–2017 is severe. SEEK is carrying
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out an influenza challenge study (FLU-v 004) in parallel
to this present study. In this challenge study, carried out
in collaboration with the National Institute of Health
(NIH), subjects will be exposed to H1N1 influenza virus
after vaccination. Blood samples will be taken before
and after vaccination so that correlation between im-
mune markers and protection can be established. Data
from the FLU-v 004 study could be extrapolated to this
study, allowing us to identify the number of subjects that
have reached a protective immune threshold in this
phase IIb study.
FLU-v has been shown to stimulate Th1 responses and
the formulation with Montanide ISA-51 enhances this
type of response, as seen in previous trials [13, 24].
Vaccine adjuvants are known to increase the response to
the vaccine antigens without being antigenic themselves
[25, 26]. The immune enhancing effect of ISA-51 is as-
sociated with the slow release of the antigen at the
immunization site, inflammation and the accumulation
of lymphocytes in draining lymph nodes [26, 27]. Mon-
tanide ISA-51 has been used in thousands of subjects in
clinical trials. Reported adverse events were mainly mild
to moderate in intensity and include pain or a reaction
at the injection site, headache and myalgia [28, 29].
Montanide ISA-51 creates a water-in-oil emulsion previ-
ously shown to enhances the cellular immune responses
when added to FLU-v [13, 24]. In fact, the previous
phase I trial showed that one administration with non-
adjuvanted FLU-v did not induce cellular responses,
whereas 80 and 100% of the volunteers receiving 250 μg
and 500 μg adjuvanted FLU-v, respectively, showed vac-
cine specific IFN-γ responses at least 2-fold higher than
their pre-vaccination level on day 21 [13]. Emulsions of
FLU-v in Montanide ISA-51 and WFI will be prepared
by passing the product from one syringe to another
locked through a connector (2-syringe mixing) in order
to produce stable and homogenous emulsions. The rea-
son for this is that vortex mixing does not give enough
shear strength to produce stable emulsions [26]. The
majority of AEs reported in the previous FLU-v trials
using Montanide ISA-51 were mild. AEs that could be
expected in the groups which receive the adjuvanted
vaccine include e.g. injection site reactions, pain, ery-
thema and tenderness; however, in order to minimize
the AEs the vaccine volume has been halved and the lo-
cation of the injection has been changed from the fore-
arm to the upper section of the arm.
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